Health News

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic vaccines against cancers and infectious diseases, announced today that it has entered into a product development collaboration agreement with its affiliate, VGX International Inc., to co-develop Inovio’s SynCon therapeutic vaccines for hepatitis B and C infections.

Read more

Filed under: Pharmacy News
Tags: cancer, Hepatitis, Pharmacy

Related posts

• Transgene, Inovio and ChronTech collaborate for novel vaccine phase I trial in HCV (0)
  Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today it has signed a collaboration agreement with Transgene S.A. and ChronTech Pharma AB to evaluate a novel therapeutic vaccination strategy against genotype 1 hepatitis C virus in a phase I clinical study. Read more [tags] Pharmacy News [...]
  
  
• Studies on effectiveness of new HCV therapies presented at 76th ACG meeting (0)
  Studies reporting on the effectiveness of new therapies for chronic Hepatitis C virus are among the clinical science presented at the American College of Gastroenterology's 76th Annual Scientific Meeting, where investigators also presented findings from an age-based risk assessment and screening intervention for Hepatitis C among Baby Boomers, patients aged 50-65, who saw a gastroenterologist [...]
  
  
• Novelos Therapeutics’ NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint (0)
  Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the primary endpoint of improvement in overall survival was not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Detailed [...]
  
  
• Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer (0)
  Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the 725th event (patient death) has been reached in its pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy. Read more [tags] Pharmacy News [/tags]
  
  
• Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints (0)
  Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that primary and secondary endpoints were not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its lead product, NOV-002, in combination with first-line chemotherapy. Read more [tags] Pharmacy News [/tags]